Unknown

Dataset Information

0

Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies.


ABSTRACT: BACKGROUND:Artemisinin resistance in Plasmodium falciparum lengthens parasite clearance half-life during artemisinin monotherapy or artemisinin-based combination therapy. Absence of in-vitro and ex-vivo correlates of artemisinin resistance hinders study of this phenotype. We aimed to assess whether an in-vitro ring-stage survival assay (RSA) can identify culture-adapted P falciparum isolates from patients with slow-clearing or fast-clearing infections, to investigate the stage-dependent susceptibility of parasites to dihydroartemisinin in the in-vitro RSA, and to assess whether an ex-vivo RSA can identify artemisinin-resistant P falciparum infections. METHODS:We culture-adapted parasites from patients with long and short parasite clearance half-lives from a study done in Pursat, Cambodia, in 2010 (registered with ClinicalTrials.gov, number NCT00341003) and used novel in-vitro survival assays to explore the stage-dependent susceptibility of slow-clearing and fast-clearing parasites to dihydroartemisinin. In 2012, we implemented the RSA in prospective parasite clearance studies in Pursat, Preah Vihear, and Ratanakiri, Cambodia (NCT01736319), to measure the ex-vivo responses of parasites from patients with malaria. Continuous variables were compared with the Mann-Whitney U test. Correlations were analysed with the Spearman correlation test. FINDINGS:In-vitro survival rates of culture-adapted parasites from 13 slow-clearing and 13 fast-clearing infections differed significantly when assays were done on 0-3 h ring-stage parasites (10·88% vs 0·23%; p=0·007). Ex-vivo survival rates significantly correlated with in-vivo parasite clearance half-lives (n=30, r=0·74, 95% CI 0·50-0·87; p<0·0001). INTERPRETATION:The in-vitro RSA of 0-3 h ring-stage parasites provides a platform for the molecular characterisation of artemisinin resistance. The ex-vivo RSA can be easily implemented where surveillance for artemisinin resistance is needed. FUNDING:Institut Pasteur du Cambodge and the Intramural Research Program, NIAID, NIH.

SUBMITTER: Witkowski B 

PROVIDER: S-EPMC5015432 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies.

Witkowski Benoit B   Amaratunga Chanaki C   Khim Nimol N   Sreng Sokunthea S   Chim Pheaktra P   Kim Saorin S   Lim Pharath P   Mao Sivanna S   Sopha Chantha C   Sam Baramey B   Anderson Jennifer M JM   Duong Socheat S   Chuor Char Meng CM   Taylor Walter R J WR   Suon Seila S   Mercereau-Puijalon Odile O   Fairhurst Rick M RM   Menard Didier D  

The Lancet. Infectious diseases 20130911 12


<h4>Background</h4>Artemisinin resistance in Plasmodium falciparum lengthens parasite clearance half-life during artemisinin monotherapy or artemisinin-based combination therapy. Absence of in-vitro and ex-vivo correlates of artemisinin resistance hinders study of this phenotype. We aimed to assess whether an in-vitro ring-stage survival assay (RSA) can identify culture-adapted P falciparum isolates from patients with slow-clearing or fast-clearing infections, to investigate the stage-dependent  ...[more]

Similar Datasets

| S-EPMC4992992 | biostudies-literature
| S-EPMC3807790 | biostudies-literature
| S-EPMC5007947 | biostudies-literature
| S-EPMC4200124 | biostudies-literature
| S-EPMC5522704 | biostudies-literature
| S-EPMC6105667 | biostudies-literature
| S-EPMC3786328 | biostudies-literature
| S-EPMC3495232 | biostudies-literature
| S-EPMC5154433 | biostudies-literature
| S-EPMC3360685 | biostudies-literature